Substituted heterocycle fused gamma-carbolines

Details Substituted heterocycle fused gamma-carbolines Substituted heterocycle fused gamma-carbolines

C - Chemistry, Metallurgy

07

D

C07D 471/16 (2006.01) A61K 31/4985 (2006.01) A61K 31/5517 (2006.01) A61K 31/554 (2006.01) A61P 25/00 (2006.01) C07D 209/00 (2006.01) C07D 221/00 (2006.01) C07D 221/18 (2006.01) C07D 223/00 (2006.01) C07D 223/32 (2006.01) C07D 241/00 (2006.01) C07D 243/00 (2006.01) C07D 471/06 (2006.01) C07D 487/16 (2006.01) C07D 491/06 (2006.01) C07D 495/06 (2006.01) C07D 513/16 (2006.01) C07D 519/00 (2006.01)

Patent

CA 2374239

The present invention is directed to certain novel compounds represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6a, R6b, R7, R8, R9, X, b, k, m, and n, and the dashed lines are described herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including obesity, anxiety, depression, psychosis, schizophrenia, sleep disorders, sexual disorders, migraine, conditions associated with cephalic pain, social phobias, and gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility.

La présente invention concerne certains nouveaux composés représentés par la formule (I) ou bien les formes salines pharmaceutiquement acceptables de ces derniers. Dans la formule R?1¿, R?5¿, R?6a¿, R?6b¿, R?7¿, R?8¿, R?9¿, X, b, k, m, et n, ainsi que les traits discontinus sont tels que dans le descriptif. La présente invention concerne également des formulations pharmaceutiques contenant ces nouveaux composés en tant qu'ingrédients actifs et l'utilisation de ces nouveaux composés et desdites formulations les contenant dans le traitement de certaines maladies. Les composés de la présente invention sont des agonistes et des antagonistes de la sérotonine et sont utiles pour traiter ou prévenir des troubles du système nerveux central tels que l'obésité, l'anxiété, la dépression, la psychose, la schizophrénie, les troubles du sommeil, les troubles sexuels, la migraine, les états associés aux douleurs des céphalées, aux phobies sociales et aux troubles gastro-intestinaux tels que le dysfonctionnement de la motilité du tractus gastro-intestinal.

Affiliated with

Also associated with

Rating

Substituted heterocycle fused gamma-carbolines does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Substituted heterocycle fused gamma-carbolines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted heterocycle fused gamma-carbolines will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1638026